Jill Marie Broadfoot - 05 Jan 2024 Form 4 Insider Report for aTYR PHARMA INC (ATYR)

Role: Chief Financial Officer
Signature: /s/ Nancy E. Denyes, attorney-in-fact
Issuer symbol: ATYR
Transactions as of: 05 Jan 2024
Net transactions value: $0
Form type: 4
Filing time: 09 Jan 2024, 19:33:59 UTC
Previous filing: 13 Dec 2023
Next filing: 06 Feb 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	LIFE	Common Stock						18,661	05 Jan 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LIFE	Employee Stock Option (right to buy)	Award	$0	+150,000		$0.000000	150,000	05 Jan 2024	Common Stock	150,000	$1.50	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 1,025 shares acquired on May 15, 2023 and 2,176 shares acquired on November 15, 2023 under the Company's 2015 Employee Purchase Plan.
F2	The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning February 5, 2024, such that this option will be fully exercisable on January 5, 2028. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.